Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Rajneet K. Oberoi"'
Autor:
Shichang Miao, Peter Staehr, Ezra Tai, Borje Darpo, Hongqi Xue, Danielle Armas, Kenneth Webster, Rajneet K. Oberoi
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 7, Pp n/a-n/a (2024)
Abstract This phase I thorough QTc, double‐blind, randomized, placebo‐ and positive‐controlled, parallel group, multiple‐dose study evaluated avacopan's effect on cardiac repolarization using concentration‐QTc (C‐QTc) as the primary analy
Externí odkaz:
https://doaj.org/article/a9cf4106b51344e988533b466eaadf9d
Autor:
Hanze Zhang, Pegah Jafarinasabian, Shauna Hutton, Siddique Abbasi, Mia Mackowski, Rajneet K. Oberoi, Stephen Flach, Edward Lee, Sandeep Dutta, Ashit Trivedi
Publikováno v:
Clinical Pharmacology in Drug Development. 10:1442-1451
Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction. OM is primarily eliminated via metabolism mediated by multiple cytochrome P450 enzymes. This
Autor:
Hanze Zhang, Edward Lee, Marintan Spring, Siddique Abbasi, Pegah Jafarinasabian, Ashit Trivedi, Rajneet K. Oberoi, Stephen Flach, Sandeep Dutta
Publikováno v:
Clinical Drug Investigation. 41:647-652
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure with reduced ejection fraction. The objective of this study was to evaluate the potential for OM to affect the pharmacokinetics of metformin
Publikováno v:
Clinical Therapeutics. 42:1317-1329
Purpose Fixed-dose combination glecaprevir (GLE) 300 mg + pibrentasvir (PIB) 120 mg is an orally administered once daily antiviral regimen approved for the treatment of hepatitis C virus (HCV) infection. The objective of this study was to evaluate th
Autor:
Chih-Wei Lin, Rajneet K. Oberoi, Sven Mensing, Wei Liu, Hiromitsu Kumada, Koji Kato, Doerthe Eckert, Margaret Burroughs, Kazuaki Chayama, Ahmed Abbas Suleiman
Publikováno v:
The Journal of Clinical Pharmacology. 60:331-339
Glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg once daily (Mavyret/Maviret) is an all-oral, pangenotypic, interferon- and ribavirin-free combination regimen approved for the treatment of chronic hepatitis C virus (HCV) infection. The objective of
Autor:
Rajneet K. Oberoi, Bianca Terminello, Ashit Trivedi, Stephen Flach, Pegah Jafarinasabian, Edward Lee, Siddique Abbasi, Mary Ann Simiens, Mia Mackowski, Hanze Zhang, Sandeep Dutta
Publikováno v:
Biopharmaceuticsdrug dispositionREFERENCES. 42(7)
Omecamtiv mecarbil (OM) is a cardiac myosin activator in clinical development for the treatment of heart failure. The effect of food on the pharmacokinetics (PK) of 25, 37.5, and 50 mg strength modified release (MR) tablets and the bioequivalence of
Autor:
Hanze Zhang, Rajneet K. Oberoi, Stephen Flach, Siddique Abbasi, Sandeep Dutta, Ashit Trivedi, Pegah Jafarinasabian, Edward Lee
Publikováno v:
Clinical Pharmacokinetics
Background and Objective Omecamtiv mecarbil is a novel selective cardiac myosin activator (myotrope) under investigation for the treatment of heart failure with reduced ejection fraction. The objective of this clinical study was to estimate the effec
Publikováno v:
Clinical pharmacokinetics. 59(5)
Risankizumab, a humanized monoclonal interleukin-23 antagonist antibody, has efficacy for treatment of plaque psoriasis, generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). These analyses characterized the relationships between ris
Publikováno v:
Journal of Pharmaceutical Sciences. 107:1724-1730
Glecaprevir (GLE) and pibrentasvir (PIB) are direct-acting antivirals coformulated as a combination tablet for once-daily treatment of chronic hepatitis C virus infection. The objective of this study was to evaluate the effect of different methods of
Autor:
Kazuo Notsumata, Hiromitsu Kumada, Atsushi Naganuma, Kazuaki Chayama, Margaret Burroughs, Ken Sato, Tami Pilot-Matias, Yukio Osaki, Rebecca Redman, Bo Fu, Tomofumi Atarashi, Katia Alves, Makoto Nakamuta, Satoru Saito, Fumitaka Suzuki, Koji Kato, Rajneet K. Oberoi, David Pugatch, Hidenori Toyoda, Koichi Takaguchi, Tsunamasa Watanabe, Masanori Atsukawa
Publikováno v:
Hepatology (Baltimore, Md.)
Glecaprevir (nonstructural protein 3/4A protease inhibitor) and pibrentasvir (nonstructural protein 5A inhibitor) (G/P), a coformulated once‐daily, all oral, ribavirin (RBV)‐free, direct‐acting antiviral regimen, was evaluated for safety and ef